

# Victor E Velculescu

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7753232/victor-e-velculescu-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189  
papers

78,096  
citations

103  
h-index

232  
g-index

232  
ext. papers

88,023  
ext. citations

17.8  
avg, IF

7.4  
L-index

#	Paper	IF	Citations
189	Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer. <i>Studies in Health Technology and Informatics</i> , <b>2022</b> ,	0.5	
188	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1910-1920	50.5	14
187	A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	2
186	Modeling cell-free DNA fragment size densities for non-invasive detection of cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3058-3058	2.2	
185	Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4042-4042	2.2	
184	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , <b>2021</b> , 596, 126-132	50.4	40
183	Detection and characterization of lung cancer using cell-free DNA fragmentomes. <i>Nature Communications</i> , <b>2021</b> , 12, 5060	17.4	21
182	Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 1430-1437	5.1	6
181	High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 396-408	12.5	38
180	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 525	17.4	64
179	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1327-1337	12.9	46
178	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 99-111	15.4	67
177	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. <i>Cell Reports Medicine</i> , <b>2020</b> , 1, 100139	18	17
176	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. <i>Nature Communications</i> , <b>2020</b> , 11, 3726	17.4	61
175	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1871-1879	8.9	4
174	Conserved Interferon- $\gamma$ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , <b>2020</b> , 38, 500-515.e3	24.3	75
173	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer <b>2020</b> , 8,		40

172	Genomic characterization of malignant progression in neoplastic pancreatic cysts. <i>Nature Communications</i> , <b>2020</b> , 11, 4085	17.4	27
171	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7287-7293	13.9	25
170	Combined MEK and BCL-2/X Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 642-655	6.1	26
169	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , <b>2019</b> , 570, 385-389	50.4	339
168	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4973-4984	12.9	55
167	Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3425-3435	7.5	9
166	Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 142-142	2.2	10
165	Early shifts in immune cell subsets to predict response to immune checkpoint blockade in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 105-105	2.2	1
164	Genome-wide cell-free DNA fragmentation profiling for early cancer detection.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3018-3018	2.2	
163	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 <b>2019</b> , 7, 40		28
162	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7024-7034	12.9	48
161	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 1204-1213	10.1	50
160	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 1214-1225	10.1	117
159	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1976-1986	59.2	865
158	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 888-899	12.5	60
157	Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer <b>2018</b> ,		2
156	Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 11510-11510	2.2	1
155	Circulating tumor DNA dynamics in resectable gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4069-4069	2.2	1

154	Immune checkpoint inhibition in elderly non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 137-137	2.2	1
153	Pan-Cancer assessment of tumor mutational burden using a comprehensive genomic profiling assay.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 157-157	2.2	1
152	Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4140-TPS4140	2.2	
151	American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member InstitutionsSPerspectives. <i>JCO Clinical Cancer Informatics</i> , <b>2018</b> , 2, 1-14	5.2	13
150	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 28561-28571	3.3	92
149	Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	3
148	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. <i>Cell Reports</i> , <b>2018</b> , 25, 2617-2633	10.6	49
147	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	44
146	AACR Project GENIE: Powering Precision Medicine through an International Consortium. <i>Cancer Discovery</i> , <b>2017</b> , 7, 818-831	24.4	629
145	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , <b>2017</b> , 77, 1510-1541	10.1	81
144	Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 375-384	4.5	10
143	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , <b>2017</b> , 7, 264-276	24.4	491
142	Cancer DNA in the Circulation: The Liquid Biopsy. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1272-1274	27.4	55
141	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , <b>2017</b> , 8, 1093	17.4	325
140	Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. <i>Cancer Cell</i> , <b>2017</b> , 32, 360-376.e6	24.3	116
139	Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 572-582	8.7	18
138	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	537
137	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <i>Cell</i> , <b>2017</b> , 171, 1284-1300.e21	56.2	215

136	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2471-2477	12.9	109
135	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1263-1273	12.9	67
134	Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer <b>2017</b> ,		15
133	Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8508-8508	2.2	18
132	Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 11971	17.4	125
131	Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20005-e20005	2.2	1
130	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1746-56	6.1	37
129	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , <b>2015</b> , 6, 7686	17.4	279
128	Personalized genomic analyses for cancer mutation discovery and interpretation. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 283ra53	17.5	281
127	Notch1 mutations are drivers of oral tumorigenesis. <i>Cancer Prevention Research</i> , <b>2015</b> , 8, 277-286	3.2	64
126	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , <b>2015</b> , 526, 263-7	50.4	310
125	Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 97-103	4.9	52
124	Abstract 619: Identification of clinically actionable genomic alterations in the tumor and circulation of pancreatic cancer patients <b>2015</b> ,		3
123	Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15213-e15213	2.2	3
122	Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1529-1529	2.2	1
121	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. <i>Nature Communications</i> , <b>2014</b> , 5, 5006	17.4	120
120	Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2476-84	12.9	118
119	Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. <i>Cancer Discovery</i> , <b>2014</b> , 4, 650-61	24.4	473

118	Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra24	17.5	2741
117	Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. <i>Epigenetics</i> , <b>2014</b> , 9, 1031-46	5.7	105
116	Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2947-58	12.9	34
115	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade <b>2014</b> , 2, 42		148
114	Cancer genome landscapes. <i>Science</i> , <b>2013</b> , 339, 1546-58	33.3	5058
113	Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 1002-15	6.1	80
112	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , <b>2013</b> , 45, 1470-1473	36.3	464
111	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 6021-6	11.5	968
110	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. <i>Nature Genetics</i> , <b>2013</b> , 45, 12-7	36.3	300
109	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E364-9	5.6	157
108	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discovery</i> , <b>2013</b> , 3, 658-73	24.4	489
107	Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. <i>Oncotarget</i> , <b>2013</b> , 4, 1856-7	3.3	35
106	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. <i>Human Mutation</i> , <b>2012</b> , 33, 100-3	4.7	230
105	Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 162ra154	17.5	463
104	Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). <i>Journal of Proteome Research</i> , <b>2012</b> , 11, 5556-63	5.6	13
103	Low-grade serous carcinomas of the ovary contain very few point mutations. <i>Journal of Pathology</i> , <b>2012</b> , 226, 413-20	9.4	154
102	The predictive capacity of personal genome sequencing. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 133ra58	17.5	147
101	ATM mutations in patients with hereditary pancreatic cancer. <i>Cancer Discovery</i> , <b>2012</b> , 2, 41-6	24.4	365

100	Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes. <i>Molecular Cancer Research</i> , <b>2012</b> , 10, 739-49	6.6	13
99	Response to Comments on "The Predictive Capacity of Personal Genome Sequencing". <i>Science Translational Medicine</i> , <b>2012</b> , 4, 135lr3-135lr3	17.5	0
98	Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. <i>Cancer Discovery</i> , <b>2012</b> , 2, 899-905	24.4	301
97	Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4257-65	12.9	101
96	Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6339-47	12.9	163
95	Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3068-3068	2.2	
94	The genetic landscape of the childhood cancer medulloblastoma. <i>Science</i> , <b>2011</b> , 331, 435-9	33.3	576
93	Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 1442-7	5.8	72
92	DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. <i>Science</i> , <b>2011</b> , 331, 1199-203	33.3	1252
91	Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. <i>Science</i> , <b>2011</b> , 333, 1154-7	33.3	1331
90	Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. <i>Molecular Cancer</i> , <b>2011</b> , 10, 17	42.1	44
89	Mutations in CIC and FUBP1 contribute to human oligodendroglioma. <i>Science</i> , <b>2011</b> , 333, 1453-5	33.3	399
88	Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. <i>Nature Genetics</i> , <b>2011</b> , 43, 828-9	36.3	342
87	Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1591-602	12.9	198
86	Understanding the enemy. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 98ps37	17.5	4
85	Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. <i>Cancer Research</i> , <b>2011</b> , 71, 3471-81	10.1	9
84	Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2011</b> , 25, 1908-10	10.7	26
83	Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. <i>Nature</i> , <b>2010</b> , 464, 610-4	50.4	415

82	International network of cancer genome projects. <i>Nature</i> , <b>2010</b> , 464, 993-8	50.4	1613
81	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. <i>Nature</i> , <b>2010</b> , 467, 1114-7	57.4	1834
80	Development of personalized tumor biomarkers using massively parallel sequencing. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 20ra14	17.5	401
79	Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 2598-603	11.5	97
78	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. <i>Science</i> , <b>2010</b> , 330, 228-31	33.3	915
77	Patient-oriented gene set analysis for cancer mutation data. <i>Genome Biology</i> , <b>2010</b> , 11, R112	18.3	54
76	Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. <i>Science</i> , <b>2009</b> , 324, 217	33.3	608
75	Mutant metabolic enzymes are at the origin of gliomas. <i>Cancer Research</i> , <b>2009</b> , 69, 9157-9	10.1	117
74	Genetic mutations associated with cigarette smoking in pancreatic cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 3681-8	10.1	88
73	SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4674-9	12.9	275
72	Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 12921-5	11.5	112
71	Identification of microbial DNA in human cancer. <i>BMC Medical Genomics</i> , <b>2009</b> , 2, 22	3.7	22
70	Sensitive digital quantification of DNA methylation in clinical samples. <i>Nature Biotechnology</i> , <b>2009</b> , 27, 858-63	44.5	273
69	Design and analysis issues in genome-wide somatic mutation studies of cancer. <i>Genomics</i> , <b>2009</b> , 93, 17-21	1.3	75
68	IDH1 and IDH2 mutations in gliomas. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 765-73	59.2	4220
67	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. <i>Science</i> , <b>2009</b> , 325, 1555-9	33.3	680
66	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 1597-601	5.8	339
65	Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. <i>Cancer Research</i> , <b>2009</b> , 69, 6660-7	10.1	344



64	Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. <i>BMC Cancer</i> , <b>2008</b> , 8, 87	4.8	32
63	The antisense transcriptomes of human cells. <i>Science</i> , <b>2008</b> , 322, 1855-7	33.3	436
62	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. <i>Science</i> , <b>2008</b> , 321, 1801-6	33.3	3223
61	Epitope landscape in breast and colorectal cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 889-92	10.1	328
60	Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3443-8	11.5	314
59	Defining the blueprint of the cancer genome. <i>Carcinogenesis</i> , <b>2008</b> , 29, 1087-91	4.6	51
58	TRAB: testing whether mutation frequencies are above an unknown background. <i>Statistical Applications in Genetics and Molecular Biology</i> , <b>2008</b> , 7, Article11	1.2	2
57	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 16224-9	11.5	230
56	Comparative lesion sequencing provides insights into tumor evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 4283-8	11.5	616
55	An integrated genomic analysis of human glioblastoma multiforme. <i>Science</i> , <b>2008</b> , 321, 1807-12	33.3	4419
54	Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. <i>PLoS Medicine</i> , <b>2008</b> , 5, e114	11.6	113
53	The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. <i>Science</i> , <b>2007</b> , 318, 1744-8	33.3	430
52	Digital karyotyping. <i>Nature Protocols</i> , <b>2007</b> , 2, 1973-86	18.8	22
51	The genomic landscapes of human breast and colorectal cancers. <i>Science</i> , <b>2007</b> , 318, 1108-13	33.3	2717
50	Large-scale identification of novel transcripts in the human genome. <i>Genome Research</i> , <b>2007</b> , 17, 287-92	9.7	15
49	Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 4060-4	11.5	158
48	Genetic progression and the waiting time to cancer. <i>PLoS Computational Biology</i> , <b>2007</b> , 3, e225	5	280
47	Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. <i>Cancer Research</i> , <b>2007</b> , 67, 9364-70	10.1	124

46	A multidimensional analysis of genes mutated in breast and colorectal cancers. <i>Genome Research</i> , <b>2007</b> , 17, 1304-18	9.7	106
45	Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. <i>Human Mutation</i> , <b>2006</b> , 27, 1060-1	4.7	73
44	Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 779-85	4.6	149
43	Recurrent KRAS codon 146 mutations in human colorectal cancer. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 928-32	4.6	171
42	Homozygous deletion of MKK4 in ovarian serous carcinoma. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 630-4	4.6	43
41	The colorectal microRNAome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 3687-92	11.5	797
40	The consensus coding sequences of human breast and colorectal cancers. <i>Science</i> , <b>2006</b> , 314, 268-74	33.3	2832
39	The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. <i>Nature Biotechnology</i> , <b>2006</b> , 24, 1573-80	44.5	105
38	Implications of micro-RNA profiling for cancer diagnosis. <i>Oncogene</i> , <b>2006</b> , 25, 6220-7	9.2	214
37	Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance <b>2006</b> , 531-540		
36	Mutational analysis of gene families in human cancer. <i>Current Opinion in Genetics and Development</i> , <b>2005</b> , 15, 5-12	4.9	40
35	Distinct epigenetic changes in the stromal cells of breast cancers. <i>Nature Genetics</i> , <b>2005</b> , 37, 899-905	36.3	423
34	Colorectal cancer: mutations in a signalling pathway. <i>Nature</i> , <b>2005</b> , 436, 792	50.4	452
33	Mutant PIK3CA promotes cell growth and invasion of human cancer cells. <i>Cancer Cell</i> , <b>2005</b> , 7, 561-73	24.3	726
32	Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. <i>Cancer Research</i> , <b>2005</b> , 65, 919-24	10.1	110
31	The PIK3CA gene is mutated with high frequency in human breast cancers. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 772-5	4.6	536
30	Oncogenic mutations of PIK3CA in human cancers. <i>Cell Cycle</i> , <b>2004</b> , 3, 1221-4	4.7	384
29	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. <i>Cancer Research</i> , <b>2004</b> , 64, 8816-20	10.1	404

28	Mutational analysis of the tyrosine phosphatome in colorectal cancers. <i>Science</i> , <b>2004</b> , 304, 1164-6	33.3	431
27	Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. <i>Cancer Research</i> , <b>2004</b> , 64, 5048-50	10.1	290
26	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 3089-94	11.5	163
25	Inactivation of hCDC4 can cause chromosomal instability. <i>Nature</i> , <b>2004</b> , 428, 77-81	50.4	464
24	High frequency of mutations of the PIK3CA gene in human cancers. <i>Science</i> , <b>2004</b> , 304, 554	33.3	2657
23	Somatic mutations of EGFR in colorectal cancers and glioblastomas. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2883	59.2	255
22	Three classes of genes mutated in colorectal cancers with chromosomal instability. <i>Cancer Research</i> , <b>2004</b> , 64, 2998-3001	10.1	165
21	Mutational analysis of the tyrosine kinome in colorectal cancers. <i>Science</i> , <b>2003</b> , 300, 949	33.3	392
20	PRL-3 expression in metastatic cancers. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 5607-15	12.9	133
19	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. <i>Nature</i> , <b>2002</b> , 418, 934	50.4	962
18	Using the transcriptome to annotate the genome. <i>Nature Biotechnology</i> , <b>2002</b> , 20, 508-12	44.5	528
17	Digital karyotyping. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 16156-61	11.5	191
16	Prevalence of somatic alterations in the colorectal cancer cell genome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 3076-80	11.5	163
15	Allelic variation in human gene expression. <i>Science</i> , <b>2002</b> , 297, 1143	33.3	567
14	Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. <i>Nature Genetics</i> , <b>2001</b> , 28, 184-7	36.3	524
13	A phosphatase associated with metastasis of colorectal cancer. <i>Science</i> , <b>2001</b> , 294, 1343-6	33.3	539
12	Changes in gene expression associated with developmental arrest and longevity in <i>Caenorhabditis elegans</i> . <i>Genome Research</i> , <b>2001</b> , 11, 1346-52	9.7	186
11	Analysing uncharted transcriptomes with SAGE. <i>Trends in Genetics</i> , <b>2000</b> , 16, 423-5	8.5	186

10	Genes expressed in human tumor endothelium. <i>Science</i> , <b>2000</b> , 289, 1197-202	33.3	1583
9	Analysis of human transcriptomes. <i>Nature Genetics</i> , <b>1999</b> , 23, 387-8	36.3	639
8	Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes--SAGE and its use in global gene expression analysis. <i>Science</i> , <b>1999</b> , 286, 1491-2	33.3	40
7	NORF5/HUG1 is a component of the MEC1-mediated checkpoint response to DNA damage and replication arrest in <i>Saccharomyces cerevisiae</i> . <i>Molecular and Cellular Biology</i> , <b>1999</b> , 19, 7041-9	4.8	89
6	High-throughput gene expression analysis using SAGE. <i>Drug Discovery Today</i> , <b>1998</b> , 3, 152-159	8.8	35
5	Gene expression profiles in normal and cancer cells. <i>Science</i> , <b>1997</b> , 276, 1268-72	33.3	1217
4	Characterization of the yeast transcriptome. <i>Cell</i> , <b>1997</b> , 88, 243-51	56.2	924
3	WAF1, a potential mediator of p53 tumor suppression. <i>Cell</i> , <b>1993</b> , 75, 817-25	56.2	7436
2	Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk		1
1	Evaluation of machine learning methods to predict peptide binding to MHC Class I proteins		18